Ielasi L, Tonnini M, Piscaglia F, Serio I. Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia. World J Hepatol 2023; 15(5): 675-687 [PMID: 37305373 DOI: 10.4254/wjh.v15.i5.675]
Corresponding Author of This Article
Luca Ielasi, MD, Doctor, Department of Medical and Surgical Sciences, University of Bologna, Via Albertoni, 15, Bologna 40138, Italy. luca.ielasi.kr@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2023; 15(5): 675-687 Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.675
Table 1 Curaçao diagnostic criteria of hereditary hemorrhagic teleangiectasia
Curaçao criteria
Description
Epistaxis
Spontaneous and recurrent
Teleangiectases
Multiple, at characteristic sites: Lips, oral cavity, fingers, nose
Visceral lesions
GI telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs
Family history
A first degree relative with HHT
Number of criteria
HHT diagnosis
3-4
Definite
2
Possible
0-1
Unlikely
Table 2 Genes responsible for hereditary hemorrhagic teleangiectasia, phenotypes and liver involvement prevalence
Gene
Protein
Location
Phenotype
Liver involvement prevalence
ENG
Endoglin
9q34.11
HHT1
7.6%-43.0%
ACVLR1
ALK1
12q13.13
HHT2
40.6%-57.6%
MADH4
Smad4
18q21.1
PJ-HHT
33.3%
GDF2
BMP9
10q11.22
HHT-like
Unknown
RASA-1
p120-RasGAP
5q14.3
CM-AVM
Unknown
Table 3 Clinical Scoring Index for clinical probability of significant liver disease in hereditary hemorrhagic teleangiectasia patients[25]
Criteria
Points
Age at presentation (yr)
> 47
1
≤ 47
0
Sex
Female
1
Male
0
Hb at presentation (g/dL)
< 8
3
8-12
2
12-16
1
> 16
0
ALP at presentation (IU/L)
> 300
4
225-300
3
150-224
2
75-149
1
> 75
0
Clinical Scoring Index
Clinical probability of significant liver disease
≤ 2
Low
(0.4%-3.2%)
3-6
Intermediate
(8.2%-64.1%)
≥ 7
High
(82.9%-93.0%)
Table 4 Doppler ultrasound grading of hepatic vascular malformations in hereditary hemorrhagic teleangiectasia patients[24]
VMs grade
Doppler US findings
0.5
HA diameter 5-6 mm and/or
PFV > 80 cm/sec and/or
HA RI < 0.55 and/or
Peripheral hepatic hypervascularization
1
HA dilation > 6 mm (only extrahepatic) and
PFV > 80 cm/sec and/or
HA RI < 0.55 and/or
2
HA dilation intra- and extrahepatic and
PFV > 80 cm/sec
Possible flow abnormality in portal and/or hepatic veins
3
Complex changes in HA and its branches with marked flow abnormalities
Flow abnormality in portal and/or hepatic veins
4
Decompensation of arteriovenous shunt with dilatation of portal and/or hepatic vein and marked flow abnormalities in both arteries and vein/s
Citation: Ielasi L, Tonnini M, Piscaglia F, Serio I. Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia. World J Hepatol 2023; 15(5): 675-687